RxDoctor Payments Data

Soha Mousa, MD

Rheumatology · Liberty Township, OHNPI 1356300172

Payments from drug & device makers

$10,405in general payments, 2019–2025

Across 498 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Amgen$2K
  • AbbVie$2K
  • UCB, Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$518
  • Lilly USA, LLC$492
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$2,94528%
  • Grants$2402%
  • Food & beverage$7,02367%
  • Education$1982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,405 in reported general payments places this provider in the 75th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,799,476
Medicare patients
346
Services billed
139,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab60$510,810
Cosentyx Sensoready PenSecukinumab20$282,745
Orencia ClickjectAbatacept44$246,779
RinvoqUpadacitinib38$234,983
Enbrel MiniEtanercept17$162,526
OtezlaApremilast17$93,470
OrenciaAbatacept14$83,262
XeljanzTofacitinib Citrate12$69,763
BenlystaBelimumab14$65,865
Hydroxychloroquine Sulfate572$18,862
Leflunomide167$9,836
MethotrexateMethotrexate Sodium398$7,959
Mycophenolate Mofetil77$5,781
Prednisone638$4,812
Diclofenac Sodium104$4,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,728$234,98338 claims
AmgenOtezla$2,015$93,47017 claims
E.r. Squibb & Sons, L.L.C.Orencia$518$83,26214 claims
PfizerXeljanz$88$69,76312 claims
GSKBenlysta$307$65,86514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Liberty Township

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →